High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
11.01B
+6.1%
1.248
+9.48%
11.35B
+6.75%
1.335
+10.34%
11.78B
+7.37%
1.462
+9.09%
Estimates Revision
The market is revising Upward the revenue expectations for Abbott Laboratories (ABT) for FY2025, with the revenue forecasts being adjusted by 0.5% over the past three months. During the same period, the stock price has changed by 3.55%.
Revenue Estimates for FY2025
Revise Upward
+0.5%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+0.04%
In Past 3 Month
Stock Price
Go Up
+3.55%
In Past 3 Month
21 Analyst Rating
0Wall Street analysts forecast ABT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABT is 144.40 USD with a low forecast of 127.00 USD and a high forecast of 159.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Buy
3 Hold
0 Sell
Strong Buy
0Current: 134.800
Low
127.00
Averages
144.40
High
159.00
0Current: 134.800
Low
127.00
Averages
144.40
High
159.00
Jefferies
Matthew Taylor
Hold
Maintains
$135 → $137
2025-04-17
Reason
Jefferies
Matthew Taylor
Price Target
$135 → $137
2025-04-17
Maintains
Hold
Reason
Jefferies raised the firm's price target on Abbott to $137 from $135 and keeps a Hold rating on the shares after the company reported "solid" Q1 results and reaffirmed FY25 guidance despite tariffs. While the firm remains Hold rated on the shares, the analyst was "impressed by the result" and Abbott's ability to navigate tariffs and macro pressure.
Stifel
Rick Wise
Strong Buy
Maintains
$135 → $145
2025-04-17
Reason
Stifel
Rick Wise
Price Target
$135 → $145
2025-04-17
Maintains
Strong Buy
Reason
Stifel raised the firm's price target on Abbott to $145 from $135 and keeps a Buy rating on the shares. Abbott's resilient Q1 performance, reiterated 2025 guidance, and bullish commentary related to potentially increasing guidance if not for tariff headwinds, all firmly place Abbott within the "quality growth" idea category in a moment of large-scale macroeconomic uncertainty, the analyst tells investors.
Barclays
Matt Miksic
Buy
Maintains
$158 → $159
2025-04-17
Reason
Barclays
Matt Miksic
Price Target
$158 → $159
2025-04-17
Maintains
Buy
Reason
Barclays analyst Matt Miksic raised the firm's price target on Abbott to $159 from $158 and keeps an Overweight rating on the shares following the Q1 report.. The company's distributed manufacturing model and product line redundancies make its tariff risks more manageable, the analyst tells investors in a research note.
Morgan Stanley
David Lewis
Hold
Maintains
$117 → $127
2025-04-17
Reason
Morgan Stanley
David Lewis
Price Target
$117 → $127
2025-04-17
Maintains
Hold
Reason
Morgan Stanley raised the firm's price target on Abbott to $127 from $117 and keeps an Equal Weight rating on the shares. Abbott "sounded comfortable despite macro uncertainties," says the analyst, who sees "a lot to like" about Abbott's defensiveness and optionality. However, this is probably captured already by the stock's year-to-date outperformance and the stock's premium multiple, the analyst tells investors.
Wells Fargo
Lawrence Biegelsen
Buy
Maintains
$136 → $147
2025-04-17
Reason
Wells Fargo
Lawrence Biegelsen
Price Target
$136 → $147
2025-04-17
Maintains
Buy
Reason
Wells Fargo raised the firm's price target on Abbott to $147 from $136 and keeps an Overweight rating on the shares. The firm notes the company reported a Q1 EPS beat despite Dx softness. Abbott maintained 2025 guide, which now includes a few hundred-million-dollar tariff impact starting in the second half of the year. Management believes through mitigation the annualized impact would be less than 2 times this, Wells adds.
RBC Capital
Shagun Singh
Buy
Maintains
$140 → $145
2025-04-17
Reason
RBC Capital
Shagun Singh
Price Target
$140 → $145
2025-04-17
Maintains
Buy
Reason
RBC Capital analyst Shagun Singh raised the firm's price target on Abbott to $140 from $135 and keeps an Outperform rating on the shares as part of a broader research note previewing Q1 results for Medical Devices. Q1 underlying procedure volume and capital placements trends were solid with typical seasonality at play, which should position companies under coverage to beat expectations for the quarter, while FX has moved notably to favor large-cap medical device companies with international exposure, which is not factored into consensus estimates for Q1 or 2025, the analyst tells investors in a research note. Tariff impact is likely to be clarified by several companies, though many companies under coverage have low tariff exposure with a substantial U.S. manufacturing footprint or low relative exposure vs. other large caps, the firm adds.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Abbott Laboratories (ABT.N) is 25.31, compared to its 5-year average forward P/E of 24.79. For a more detailed relative valuation and DCF analysis to assess Abbott Laboratories 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
24.79
Current PE
25.31
Overvalued PE
27.13
Undervalued PE
22.45
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
19.00
Current EV/EBITDA
19.88
Overvalued EV/EBITDA
20.47
Undervalued EV/EBITDA
17.53
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
4.84
Current PS
5.12
Overvalued PS
5.26
Undervalued PS
4.42
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
ABT News & Events
Events Timeline
(ET)
2025-05-15
09:08:31
Abbott's Libre technology reduces heart hospitalization in real-world study
2025-04-29 (ET)
2025-04-29
09:07:22
Abbott announces data integration agreement with Epic
2025-04-27 (ET)
2025-04-27
17:48:01
Abbott announces new AVEIR data, initiates trial for pacing technology
Sign Up For More Events
Sign Up For More Events
News
Preview
9.0
05-15NewsfilterPinnedAbbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes
Preview
9.0
05-15NASDAQ.COMPinnedAbbott Announces New Positive Data From REFLECT Studies Of FreeStyle Libre CGM
Preview
3.0
05-16NASDAQ.COMValidea Detailed Fundamental Analysis - ABT
Sign Up For More News
People Also Watch
FAQ
What is Abbott Laboratories (ABT) stock price today?
What is Abbott Laboratories (ABT)'s business?
What is the price predicton of ABT Stock?
What is Abbott Laboratories (ABT)'s revenue for the last quarter?
What is Abbott Laboratories (ABT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Abbott Laboratories (ABT)'s fundamentals?
How many employees does Abbott Laboratories (ABT). have?